TipRanks
Ionis Pharmaceuticals (MX:IONS)
:IONS
Mexico Market
IONS
Ionis Pharmaceuticals
RESEARCH TOOLSreports

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

IONS Analyst Ratings

Strong Buy
20Ratings
Strong Buy
18 Buy
2 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Ionis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$1,565.70
▲(55.02% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $1,565.70 with a high forecast of $1,940.91 and a low forecast of $1,045.11. The average price target represents a 55.02% change from the last price of $1,010.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"959":"$959","1450":"$1,450","1941":"$1,941","1204.5":"$1,204.5","1695.5":"$1,695.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1940.91409616,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.94K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1565.6968974084211,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.57K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1045.10759024,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.05K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[959,1204.5,1450,1695.5,1941],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,960,1035.4549304738462,1110.9098609476923,1186.3647914215385,1261.8197218953846,1337.2746523692308,1412.729582843077,1488.1845133169231,1563.6394437907693,1639.0943742646155,1714.5493047384616,1790.0042352123078,1865.459165686154,{"y":1940.91409616,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,960,1006.592069031417,1053.184138062834,1099.776207094251,1146.368276125668,1192.9603451570852,1239.552414188502,1286.144483219919,1332.736552251336,1379.3286212827531,1425.92069031417,1472.5127593455873,1519.1048283770042,{"y":1565.6968974084211,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,960,966.5467377107692,973.0934754215384,979.6402131323077,986.1869508430769,992.7336885538462,999.2804262646154,1005.8271639753847,1012.3739016861539,1018.9206393969231,1025.4673771076923,1032.0141148184616,1038.5608525292307,{"y":1045.10759024,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1150,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":970,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1010,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":960,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,941Average Price Target$1,566Lowest Price Target$1,045
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on MX:IONS
Eric Joseph
Citi
Citi
$1,866.26
Buy
84.78%
Upside
Reiterated
10/28/26
Ionis: Partnered Royalty Strength and De-Risked Revenue Visibility Support Buy Rating; Price Target Reaffirmed at $100
Canaccord Genuity Analyst forecast on MX:IONS
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$1,586.32
Buy
57.06%
Upside
Reiterated
10/28/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Neurogene (NASDAQ: NGNE) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)
H.C. Wainwright Analyst forecast on MX:IONS
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$1,866.26
Buy
84.78%
Upside
Reiterated
10/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on MX:IONS
Allison Bratzel
Piper Sandler
Piper Sandler
$1,623.65
Buy
60.76%
Upside
Reiterated
10/21/26
Piper Sandler Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
BMO Capital Analyst forecast on MX:IONS
David Lebowitz
BMO Capital
BMO Capital
$1,007.78→$1,231.73
Buy
21.95%
Upside
Upgraded
10/21/26
Analyst Raises Ionis Price Target to $66 on Strong Tryngolza Launch and Undervalued sHTG Opportunity
Morgan Stanley Analyst forecast on MX:IONS
Michael Ulz
Morgan Stanley
Morgan Stanley
$1,940.91
Buy
92.17%
Upside
Reiterated
10/21/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Integra Lifesciences (NASDAQ: IART) and vTv Therapeutics (NASDAQ: VTVT)
Raymond James Analyst forecast on MX:IONS
Tiago Fauth
Raymond James
Raymond James
$1,567.66→$1,474.35
Buy
45.98%
Upside
Reiterated
10/20/26
Ionis Pharmaceuticals price target lowered to $79 from $84 at Raymond JamesIonis Pharmaceuticals price target lowered to $79 from $84 at Raymond James
UBS Analyst forecast on MX:IONS
Joon Lee
UBS
UBS
$858.48→$1,642.31
Buy
62.61%
Upside
Initiated
10/16/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Ionis Pharmaceuticals (NASDAQ: IONS)
Bank of America Securities Analyst forecast on MX:IONS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$1,698.3
Buy
68.15%
Upside
Reiterated
10/09/26
Ionis Pharmaceuticals (IONS) Receives a Buy from Bank of America Securities
RBC Capital Analyst forecast on MX:IONS
Luca Issi
RBC Capital
RBC Capital
$1,586.32
Buy
57.06%
Upside
Reiterated
10/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on MX:IONS
Justin Kim
Oppenheimer
Oppenheimer
$1,586.32
Buy
57.06%
Upside
Reiterated
09/24/26
Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
TD Cowen Analyst forecast on MX:IONS
Yaron Werber
TD Cowen
TD Cowen
$1,567.66
Buy
55.21%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT) and Ionis Pharmaceuticals (NASDAQ: IONS)
Needham Analyst forecast on MX:IONS
Joseph Stringer
Needham
Needham
$1,604.99
Buy
58.91%
Upside
Reiterated
09/23/26
Stringer Reiterates Buy on Ionis as Late-Stage Pipeline Delivers; Price Target Maintained at $86
William Blair Analyst forecast on MX:IONS
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Ionis Pharmaceuticals (NASDAQ: IONS)
J.P. Morgan Analyst forecast on MX:IONS
Jessica Fye
J.P. Morgan
J.P. Morgan
$1,306.38
Buy
29.34%
Upside
Assigned
09/22/26
Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorganIonis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on MX:IONS
Eric Joseph
Citi
Citi
$1,866.26
Buy
84.78%
Upside
Reiterated
10/28/26
Ionis: Partnered Royalty Strength and De-Risked Revenue Visibility Support Buy Rating; Price Target Reaffirmed at $100
Canaccord Genuity Analyst forecast on MX:IONS
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$1,586.32
Buy
57.06%
Upside
Reiterated
10/28/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Neurogene (NASDAQ: NGNE) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)
H.C. Wainwright Analyst forecast on MX:IONS
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$1,866.26
Buy
84.78%
Upside
Reiterated
10/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on MX:IONS
Allison Bratzel
Piper Sandler
Piper Sandler
$1,623.65
Buy
60.76%
Upside
Reiterated
10/21/26
Piper Sandler Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
BMO Capital Analyst forecast on MX:IONS
David Lebowitz
BMO Capital
BMO Capital
$1,007.78→$1,231.73
Buy
21.95%
Upside
Upgraded
10/21/26
Analyst Raises Ionis Price Target to $66 on Strong Tryngolza Launch and Undervalued sHTG Opportunity
Morgan Stanley Analyst forecast on MX:IONS
Michael Ulz
Morgan Stanley
Morgan Stanley
$1,940.91
Buy
92.17%
Upside
Reiterated
10/21/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Integra Lifesciences (NASDAQ: IART) and vTv Therapeutics (NASDAQ: VTVT)
Raymond James Analyst forecast on MX:IONS
Tiago Fauth
Raymond James
Raymond James
$1,567.66→$1,474.35
Buy
45.98%
Upside
Reiterated
10/20/26
Ionis Pharmaceuticals price target lowered to $79 from $84 at Raymond JamesIonis Pharmaceuticals price target lowered to $79 from $84 at Raymond James
UBS Analyst forecast on MX:IONS
Joon Lee
UBS
UBS
$858.48→$1,642.31
Buy
62.61%
Upside
Initiated
10/16/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Ionis Pharmaceuticals (NASDAQ: IONS)
Bank of America Securities Analyst forecast on MX:IONS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$1,698.3
Buy
68.15%
Upside
Reiterated
10/09/26
Ionis Pharmaceuticals (IONS) Receives a Buy from Bank of America Securities
RBC Capital Analyst forecast on MX:IONS
Luca Issi
RBC Capital
RBC Capital
$1,586.32
Buy
57.06%
Upside
Reiterated
10/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on MX:IONS
Justin Kim
Oppenheimer
Oppenheimer
$1,586.32
Buy
57.06%
Upside
Reiterated
09/24/26
Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
TD Cowen Analyst forecast on MX:IONS
Yaron Werber
TD Cowen
TD Cowen
$1,567.66
Buy
55.21%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT) and Ionis Pharmaceuticals (NASDAQ: IONS)
Needham Analyst forecast on MX:IONS
Joseph Stringer
Needham
Needham
$1,604.99
Buy
58.91%
Upside
Reiterated
09/23/26
Stringer Reiterates Buy on Ionis as Late-Stage Pipeline Delivers; Price Target Maintained at $86
William Blair Analyst forecast on MX:IONS
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Ionis Pharmaceuticals (NASDAQ: IONS)
J.P. Morgan Analyst forecast on MX:IONS
Jessica Fye
J.P. Morgan
J.P. Morgan
$1,306.38
Buy
29.34%
Upside
Assigned
09/22/26
Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorganIonis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
REPLReplimune Group
VSTMVerastem
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

3 Months
David LebowitzBMO Capital
Success Rate
21/34 ratings generated profit
62%
Average Return
+5.78%
Copying David Lebowitz's trades and holding each position for 3 Months would result in 61.76% of your transactions generating a profit, with an average return of +5.78% per trade.
1 Year
David LebowitzBMO Capital
Success Rate
24/34 ratings generated profit
71%
Average Return
+26.18%
Copying David Lebowitz's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +26.18% per trade.
2 Years
David LebowitzBMO Capital
Success Rate
33/34 ratings generated profit
97%
Average Return
+35.27%
Copying David Lebowitz's trades and holding each position for 2 Years would result in 97.06% of your transactions generating a profit, with an average return of +35.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
15
35
39
50
37
Buy
35
27
24
20
12
Hold
2
5
9
13
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
52
67
72
83
59
In the current month, IONS has received 49 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. IONS average Analyst price target in the past 3 months is 1,565.70.
Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$22.86 with a range of -$26.77 to -$18.04. The previous quarter’s EPS was -$12.96. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.
Next quarter’s earnings estimate for IONS is -$22.86 with a range of -$26.77 to -$18.04. The previous quarter’s EPS was -$12.96. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $3.41B with a range of $3.01B to $4.23B. The previous quarter’s sales results were $5.03B. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.
Next quarter’s sales forecast for IONS is $3.41B with a range of $3.01B to $4.23B. The previous quarter’s sales results were $5.03B. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Stock Forecast FAQ

What is MX:IONS’s average 12-month price target, according to analysts?
Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 1,565.70.
    What is MX:IONS’s upside potential, based on the analysts’ average price target?
    Ionis Pharmaceuticals has 55.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ionis Pharmaceuticals a Buy, Sell or Hold?
          Ionis Pharmaceuticals has a consensus rating of Strong Buy, which is based on 18 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Ionis Pharmaceuticals’s share price target?
            The average share price target for Ionis Pharmaceuticals is 1,565.70. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,940.91 ,and the lowest forecast is $1,045.11. The average share price target represents 55.02% Increase from the current price of $1,010.
              What do analysts say about Ionis Pharmaceuticals?
              Ionis Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of Ionis Pharmaceuticals?
                To buy shares of MX:IONS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.